Perspectives of γδ T cells in tumor immunology

Cancer Research

Volumn 67, Issue 1, 2007, Pages 5-8

  Kabelitz, Dieter ^a   Wesch, Daniela ^a   He, Wei ^b  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOBISPHOSPHONATE; APOLIPOPROTEIN A1; BISPHOSPHONIC ACID DERIVATIVE; BROMOHYDRIN PYROPHOSPHATE; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NATURAL KILLER CELL RECEPTOR; PHOSPHONIC ACID DERIVATIVE; PYROPHOSPHORIC ACID DERIVATIVE; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; LYMPHOCYTE ANTIGEN RECEPTOR; TUMOR ANTIGEN;

ANTINEOPLASTIC ACTIVITY; CELL ACTIVATION; CELL ACTIVITY; CELL INFILTRATION; CELL ISOLATION; CELL THERAPY; COLON CARCINOMA; CYTOTOXICITY; EFFECTOR CELL; EPITHELIUM CELL; HUMAN; HUMAN CELL; IMMUNOTHERAPY; KIDNEY CARCINOMA; LEUKEMIA; LYMPHOMA; MAJOR HISTOCOMPATIBILITY COMPLEX; MODULATION; MULTIPLE MYELOMA; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNOLOGY; IMMUNOLOGY; NEOPLASM;

ANTIGENS, NEOPLASM; HUMANS; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA;

EID: 33846454363     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-3069     Document Type: Review

References (20)

1. Hayday AC. γδ T cells: a right time and a right place for a conserved third way of protection. Annu Rev Immunol 2000;18:975-1026.
2. Girardi M, Oppenheim DE, Steele CR, et al. Regulation of cutaneous malignancy by γδ T cells. Science 2001;294:605-9.
3. Bonneville M, Scotet E. Human Vγ9Vδ2 T cells: promising new leads for immunotherapy of infections and tumors. Curr Opin Immunol 2006;18:1-8.
4. + T lymphocytes recognize tumor cells of epithelial origin. J Exp Med 1996;183:1681-96.
5. Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, Spies T. Broad tumor-associated expression and recognition by tumor-derived γδ T cells of MIC-A and MIC-B. Proc Natl Acad Sci U S A 1999;96:6879-84.
6. Poggi A, Venturino C, Catellani S, et al. Vδ1 T lymphocytes from B-CLL patients recognize ULBP3 expressed on leukemic B cells and up-regulated by trans-retinoic acid. Cancer Res 2004;64:9172-9.
7. Wu J, Groh V, Spies T. T cell antigen receptor engagement and specificity in the recognition of stress-inducible MHC class I-related chains by human epithelial γδ T cells. J Immunol 2002;169:1236-40.
8. Zhao J, Huang J, Chen H, Cui L, He W. Vδ1 T cell receptor binds specifically to MHC I chain related A: molecular and biochemical evidences. Biochem Biophys Res Commun 2006;339:232-40.
9. Viey E, Fromont G, Escudier B, et al. Phosphostim-activated γδ T cells kill autologous metastatic renal cell carcinoma. J Immunol 2005;174:1338-47.
10. Gober HJ, Kistowska M, Angman L, Jenö P, Mori L, De Libero G. Human T cell receptor γδ T cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med 2003;197:163-8.
11. Kunzmann V, Bauer E, Feurle J, Weißinger F, Torny HP, Wilhelm M. Stimulation of γδ T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 2000;86:384-92.
12. Corvaisier M, Moreau-Aubry A, Diez E, et al. Vγ9Vδ2 T cell response to colon carcinoma cells. J Immunol 2005;175:5481-8.
13. Scotet E, Martinez LO, Grant E, et al. Tumor recognition following Vγ9Vδ2 T cell receptor interactions wit a surface F1-ATPase-related structure and apolipoprotein A-I. Immunity 2005;22:71-80.
14. Xu C, Zhang H, Hu H, et al. γδ T cells recognize tumor cells via CDR3δ region. Mol Immunol 2007;44:302-10.
15. Das H, Groh V, Kuijl C, et al. MICA engagement by human Vγ2Vδ2 T cells enhances their antigen-dependent effector function. Immunity 2001;15:83-93.
16. Rincon-Orozco B, Kunzmann V, Wrobel P, Kabelitz D, Steinle A, Herrmann T. Activation of Vγ9Vδ2 T cells by NKG2D. J Immunol 2005;175:2144-51.
17. Kabelitz D, Pitters E, Wesch D, Zölier M. Characterization of tumor reactivity of human Vγ9Vδ2 γδ T-cells in vitro and in severe combined immunodeficiency mice in vivo. J Immunol 2004;173:6767-76.
18. Viey E, Laplace C, scudier B. Peripheral γδ T-lymphocytes as an innovative tool in immunotherapy for metastatic renal cell carcinoma. Expert Rev Anticancer Ther 2005;5:973-86.
19. Märten A, von Lilienfeld-Toal M, Büchler MW, Schmidt J. Soluble MIC is elevated in the serum of patients with pancreatic carcinoma diminishing γδ T cell cytotoxicity. Int J Cancer 2006;119:2359-65.
20. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006;6:295-307.